Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) EV/FCF
As of 5 November 2026, Haleon PLC Sponsored ADR (HLN) trades at a EV/FCF of 11.4×. Over the past ten years it has ranged from 0.0× (June 2024) to 13.5× (June 2025); the current reading is higher than 71% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 11.0× | (5.21%) |
| FY2024 | 11.6× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2024 | 12.7× | — |
| Mar 2024 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| HLN Haleon PLC Sponsored ADR | 11.4× |
| TAK Takeda Pharmaceutical Co. compare | 11.7× |
| NBIX Neurocrine Biosciences, Inc. compare | 15.5× |
| VTRS Viatris Inc. compare | 16.3× |
| ZTS Zoetis Inc. compare | 18.4× |
| UTHR United Therapeutics Corporation compare | 24.2× |
| ELAN Elanco Animal Health Incorporated compare | 42.7× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 46.2× |
| RDY Dr. Reddy's Laboratories Ltd compare | 126× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on HLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement